Get to know our clinical trials

Phase I/II clinical trial of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with unresectable or metastatic advanced cancer.

THE OBJECTIVE OF THIS STUDY IS TO FIND A SAFE DOSE OF A NEW DRUG, CALLED JK08 (IMMUNOTHERAPY ANTIBODY FUSION PROTEIN THAT ACTS ON IMMUNE CELLS AND IS DESIGNED TO IMPROVE THE CAPACITY OF THE IMMUNE SYSTEM (IN PARTICULAR, T LYMPHOCYTES AND NK LYMPHOCYTES).

Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II, MULTICENTER, OPEN-LABEL, STEPWISE DOSE ESCALATION AND DOSE EXPANSION STUDY OF JK08, AN IL-15 ANTIBODY FUSION PROTEIN TARGETING CTLA-4, IN PATIENTS WITH UNRESECTABLE OR METASTATIC LOCALLY ADVANCED CANCER .STEPWISE DOSE ESCALATION
  • Code EudraCT: 2022-000339-21
  • Protocol number: JK08.1.01
  • Promoter: Salubris Biotherapeutics, Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.